
Neurologist

No OPD information available
Alzheimer's Disease
Creutzfeldt-Jakob Disease
Dementia
Primary Lateral Sclerosis
Actinomycosis
Agnosia
Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Anti-NMDA Receptor Encephalitis
Brachial Plexopathy
CACH Syndrome
Claw Foot
Corticobasal Degeneration
Drug Induced Dyskinesia
Dysarthria
Encephalitis
Fatal Familial Insomnia
Frontotemporal Dementia
Hammer Toe
High Arch
Huntington Disease
Kuru
Lewy Body Dementia (LBD)
Memory Loss
Movement Disorders
Multiple Sclerosis (MS)
Myelitis
Primary Amyloidosis
Primary Progressive Aphasia
Teratoma of the Mediastinum
Transient Global Amnesia
Whipple Disease
Peter K. Panegyres-Fallon is a male medical professional who helps patients with various conditions like Alzheimer's Disease, Dementia, and Multiple Sclerosis. He also works with rare disorders like Kuru and Whipple Disease. Peter uses his special skills to diagnose and treat these illnesses, providing care to improve patients' health.
Peter communicates with patients in a kind and clear way, earning their trust through his expertise and compassion. He stays updated on the latest medical knowledge and research to ensure he provides the best possible care to his patients. Peter collaborates with other medical professionals, sharing his knowledge and experience to benefit his patients.
One way Peter has positively impacted patients' lives is through his research on medicinal cannabis in neurodegenerative disorders. His study aimed to find safe and effective treatments for these conditions. Additionally, Peter is involved in a clinical trial for Huntington's Disease, showing his dedication to advancing medical knowledge and improving patient outcomes.
Through his work and publications, Peter K. Panegyres-Fallon has shown a commitment to helping patients with neurological disorders live healthier and happier lives. His expertise, communication skills, and collaborative approach make him a trusted and valuable member of the medical community.
Enrollment Status: Recruiting
Published: February 28, 2024
Intervention Type:
Study Drug:
Study Phase:
